BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Whale stranded off Germany for days free again - 2Hezbollah uses ambulances, paramedic uniforms, as disguise for terrorist activity, IDF says
- 3Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- 4Iranian missile hit on Ne'ot Hovav factory leads to fear of chemical leakage
- 5Step by step instructions to Integrate Lab Precious stones into Special Adornments Pieces
- Former ‘Dancing with the Stars’ Pro Survives Plane Crash at LaGuardia That Left 2 Pilots Dead
- Extreme Manual for Picking a Camper Van
- Father and son spending Christmas together after health scares
- The most effective method to Decisively Use Open Record Rewards
- India's top court hears challenges to ruling on women's entry into temple
- Here are 10 stores where you can get a free Thanksgiving turkey
- 7 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
- Nations for Youngsters to Visit
- Poland open to German troops to help secure Ukraine ceasefire
